Luminol functionalized tin dioxide nanoparticles with catalytic effect for sensitive detection of glucose and uric acid.

Anal Chim Acta

CAS Key Laboratory of Soft Matter Chemistry, iChEM (Collaborative Innovation Center of Chemistry for Energy Materials), Department of Chemistry, University of Science and Technology of China, Hefei, 230026, PR China. Electronic address:

Published: August 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In this work, novel luminol functionalized nanoparticles (SnO@Luminol NPs) with mesoporous spherical structure were synthesized by a simple and green method, which exhibited good chemiluminescence (CL) intensity without any additional catalysts. In addition, the CL intensities generated by SnO@Luminol/HO system were linearly related to the logarithm values of HO concentrations, and CL mechanism of SnO@Luminol/HO system was investigated. On this basis, a sensitive CL method was proposed to determine glucose and uric acid. The fabricated CL method displayed wide linear ranges (glucose, 1.0 × 10 - 1.0 × 10 M; uric acid, 1.0 × 10 - 1.0 × 10 M) and low detection limits (glucose, 5.4 nM; uric acid, 6.8 nM). The proposed CL method achieved sensitive and specific glucose and uric acid detection in human serum specimens, and the measured results were consistent with the clinical diagnosis. Furthermore, as long as the product of reaction between enzyme and substrate is HO, this CL method can also be extended to other biological detection fields.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aca.2022.340070DOI Listing

Publication Analysis

Top Keywords

uric acid
20
glucose uric
12
luminol functionalized
8
sno@luminol/ho system
8
10 × 10 10 × 10 m
8
glucose
5
uric
5
acid
5
method
5
functionalized tin
4

Similar Publications

Background Hyperuricemia (HUA) frequently coexists with coronary artery disease (CAD) and is linked to adverse cardiovascular outcomes. The long-term impact of urate-lowering therapy (ULT) on clinical outcomes, including all-cause mortality and major adverse cardiovascular events (MACEs), in CAD patients after percutaneous coronary intervention (PCI) has not been determined. That was the aim of this study.

View Article and Find Full Text PDF

Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety.

Clin Kidney J

September 2025

Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Background: This study aimed to evaluate the efficacy and safety of telitacicept versus mycophenolate mofetil (MMF) in high-risk progressive immunoglobulin A nephropathy (IgAN).

Methods: This retrospective, multicentre cohort study included patients with high-risk progressive IgAN who received telitacicept or MMF therapy, both combined with low-dose steroids. Clinical data were collected from treatment initiation to 12 months.

View Article and Find Full Text PDF

Background And Aims: Obesity-related non-alcoholic fatty liver disease (NAFLD) and serum high-sensitivity C-reactive protein (hs-CRP) are known to be associated to some extent. Nevertheless, this relationship remains unclear in non-obese individuals.

Methods And Results: A prospective cohort study was conducted using data from the health check ups of employees at Zhenhai Refining and Chemical Hospital in Ningbo City.

View Article and Find Full Text PDF

Hidden confounders in the Kidney-Brain-Parkinson's Axis.

J Clin Neurosci

September 2025

Azienda Sanitaria Provinciale Catania, Catania, Italy. Electronic address:

View Article and Find Full Text PDF

A Rapid Approach for Assessing Body Fluid Matrix Effects.

J Appl Lab Med

September 2025

Department of Pathology, UC San Diego Health, San Diego, CA, United States.

Background: While clinical laboratories routinely perform automated chemistry assays on approved specimens (e.g., plasma and serum), the FDA has not evaluated the validity of these assays for nonapproved specimens (e.

View Article and Find Full Text PDF